Academic Unit of Neurology, Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
Department of Neurology, Hospital Universitario Torrecárdenas, Almería, Spain.
Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):119-127. doi: 10.1080/21678421.2023.2271517. Epub 2024 Jan 23.
The Latin American Epidemiologic study of ALS (LAENALS) aims to gather data on ALS epidemiology, phenotype, and risk factors in Cuba, Chile, and Uruguay, to understand the impact of genetic and environmental factors on ALS.
A harmonized data collection protocol was generated, and a Latin-American Spanish language Register was constructed. Patient data were collected in Uruguay in 2018, in Chile from 2017 to 2019, and in Cuba between 2017 and 2018. Statistical analysis was performed using SPSS 25.0.0 software. Crude cumulative incidence, standardized incidence, and prevalence were calculated in the population aged 15 years and older.
During 2017-2019, 90 people with ALS from Uruguay (55.6% men), 219 from Chile (54.6% men), and 49 from Cuba (55.1% men) were included. The cumulative crude incidence in 2018 was 1.73/100,000 persons in Uruguay, 1.08 in Chile and 0.195 in Cuba. Crude prevalence in 2018 was 2.19 per 100,000 persons in Uruguay, 1.39 in Chile and 0.55 in Cuba. Mean age at onset was 61.8 ± 11.96 SD years in Uruguay, 61.9 ± 10.4 SD years in Chile, and 60.21 ± 12.45 SD years in Cuba ( = 0.75). Median survival from onset was 32.43 months (21.93 - 42.36) in Uruguay, 24 months (13.5 - 33.5) in Chile, and 29 months (15 - 42.5) in Cuba ( = 0.006).
These preliminary data from LAENALS confirm the lower incidence and prevalence of ALS in counties with admixed populations. The LAENALS database is now open to other Latin American countries for harmonized prospective data collection.
拉丁美洲肌萎缩侧索硬化症(ALS)流行病学研究(LAENALS)旨在收集古巴、智利和乌拉圭的 ALS 流行病学、表型和危险因素数据,以了解遗传和环境因素对 ALS 的影响。
制定了一套协调一致的数据收集方案,并建立了一个拉丁美洲西班牙语登记处。2018 年在乌拉圭收集了患者数据,2017 年至 2019 年在智利收集了数据,2017 年至 2018 年在古巴收集了数据。使用 SPSS 25.0.0 软件进行统计分析。在 15 岁及以上人群中计算了粗累积发病率、标准化发病率和患病率。
2017 年至 2019 年期间,乌拉圭纳入 90 名 ALS 患者(55.6%为男性),智利纳入 219 名(54.6%为男性),古巴纳入 49 名(55.1%为男性)。2018 年粗累积发病率为乌拉圭 1.73/100,000 人,智利 1.08,古巴 0.195。2018 年粗患病率为乌拉圭 2.19/100,000 人,智利 1.39,古巴 0.55。乌拉圭发病年龄平均为 61.8±11.96 标准差岁,智利为 61.9±10.4 标准差岁,古巴为 60.21±12.45 标准差岁( = 0.75)。乌拉圭从发病到死亡的中位生存时间为 32.43 个月(21.93-42.36),智利为 24 个月(13.5-33.5),古巴为 29 个月(15-42.5)( = 0.006)。
LAENALS 的这些初步数据证实了混合人群国家 ALS 的发病率和患病率较低。LAENALS 数据库现在对其他拉丁美洲国家开放,以进行协调一致的前瞻性数据收集。